Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Reanimación de traumatismos con sangre entera o productos del grupo O de título bajo (TROOP)

18 de septiembre de 2026 actualizado por: Jan O. Jansen, University of Alabama at Birmingham

The goal of this clinical trial is to compare the effectiveness of unseparated whole blood (referred to as Low-Titer Group O Whole Blood) and the separate components of whole blood (including red cells, plasma, platelets, and cryoprecipitate) in critically injured patients who require large-volume blood transfusions.

Descripción general del estudio

Estado

Terminado

Descripción detallada

Trauma is one of the leading causes of death in the United States, and disproportionately affects the young, killing those who might otherwise have lived long and productive lives. Injuries account for more years of potential life lost before age 75 than any other cause. Hemorrhage remains the most common cause of preventable death after injury, and blood transfusion is an essential part of treatment. Modern blood banking practices separate donated whole blood into components. The current standard of care in trauma transfusion is the balanced administration of equal numbers of units of blood components (packed red blood cells, plasma, and platelets), effectively attempting to reconstitute whole blood. A renewed approach to blood transfusion therapy in trauma is to use whole blood from the outset, which has not been separated. Compared with component therapy, whole blood offers several potential advantages, but there are only a small number of, mostly observational, studies comparing whole blood and component therapy, and they are very heterogeneous.

The TROOP trial will include injured adults with hemorrhagic shock anticipated to require massive blood transfusions, who will be randomized to receive either whole blood (LTOWB) or blood components. This will allow a direct comparison to see if one type of transfusion is more strongly associated with improved clinical outcomes over the other.

The knowledge gained from this clinical trial will transform the way in which massively bleeding trauma patients are transfused. The trial is exceedingly well positioned to improve mortality from trauma and reduce the number of preventable deaths resulting from hemorrhagic shock.

Tipo de estudio

Intervencionista

Inscripción (Actual)

1100

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35294
        • University of Alabama at Birmingham, UAB Hospital
    • California
      • Los Angeles, California, Estados Unidos, 90033
        • Los Angeles County + University of Southern California (LAC + USC) Medical Center
    • Louisiana
      • New Orleans, Louisiana, Estados Unidos, 70112
        • University Medical Center New Orleans LCMC Health
    • Maryland
      • Baltimore, Maryland, Estados Unidos, 21201
        • University of Maryland Medical Center
    • Missouri
      • St Louis, Missouri, Estados Unidos, 63110
        • Washington University School of Medicine
    • North Carolina
      • Winston-Salem, North Carolina, Estados Unidos, 27157
        • Atrium Health Wake Forest Baptist
    • Ohio
      • Cincinnati, Ohio, Estados Unidos, 45267
        • University of Cincinnati Medical Center
    • Oregon
      • Portland, Oregon, Estados Unidos, 97239
        • Oregon Health and Sciences University Hospital
    • Pennsylvania
      • Philadelphia, Pennsylvania, Estados Unidos, 19104
        • Penn Presbyterian Medical Center
    • Texas
      • Houston, Texas, Estados Unidos, 77030
        • University of Texas Health Science Center Houston
      • San Antonio, Texas, Estados Unidos, 78229
        • University of Texas Health San Antonio and University Health System
    • Washington
      • Seattle, Washington, Estados Unidos, 98104
        • Harborview Medical Center
    • Wisconsin
      • Milwaukee, Wisconsin, Estados Unidos, 53226
        • Froedtert Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

15 años y mayores (Niño, Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Adult trauma patient (estimated age > 15 or weight > 50 kg, if age unknown)

  2. Patient taken to trauma center directly from scene

  3. Commencement of blood transfusion (PRBC, plasma or LTOWB), in pre-hospital or in-hospital setting

  4. Activation of site-specific Massive Hemorrhage Protocol or Massive Transfusion Protocol

  5. Traumatic injury with at least one of the following:

    1. Confirmed or suspected acute major bleeding
    2. Assessment of Blood Consumption (ABC) Score ≥2

Exclusion Criteria:

  1. Patients who have received, prehospital or in-hospital more than two units of LTOWB; the equivalent in components (two units of packed red blood cells and two units of plasma); or a combination of the two (more than one unit of LTOWB, one unit of packed cells, and one unit of plasma). Most trauma centers hold two units of either packed red blood cells (with two units of plasma) or two units of LTOWB in the emergency department. This stock is used to initiate transfusion, while the massive hemorrhage protocol is activated from the blood bank.
  2. Patients transferred from another hospital
  3. Children <15 years (in most communities, patients aged 15-18 years are treated at adult trauma centers, and patients in this age group frequently suffer life-threatening injuries, and will therefore be included)
  4. Known prisoners, defined as individuals involuntarily confined or detained in a penal institution (including juvenile detention, involuntary psychiatric commitment, or court-ordered residential substance abuse treatment)
  5. Moribund patients expected to die within 1 hour
  6. Patients who required an ED thoracotomy or received more than 5 consecutive minutes of cardiopulmonary resuscitation (prior to receiving randomized blood products)
  7. Patients with known "do not resuscitate" orders prior to randomization
  8. Patients who refuse the administration of blood products
  9. Individuals with a research "opt out" bracelet.
  10. Greater than 20% total body surface area (TBSA) burns
  11. Suspected inhalation injury victims
  12. Patients who are obviously pregnant on clinical examination or known to be pregnant as provided by the subject or legally authorized representative

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Doble

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: LTOWB

Participants randomized to receive (Low Titer O Whole Blood [LTOWB])

Participants will receive Low Titer O Whole Blood administered intravenously or intraosseously.

Comparador activo: Components

Participants randomized to receive the component blood products.

Participants will receive separated blood components (i.e., units of red cells, plasma, platelets, and cryoprecipitate) co-administered intravenously or intraosseously.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
6-hour Mortality
Periodo de tiempo: First 6 hours after randomization

Participant vital status at 6-hours following randomization (randomization defined as product container is opened for administration to participant)

First 6 hours after randomization

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
24-hour Mortality
Periodo de tiempo: First 24 hours after randomization

Participant vital status at 24-hours following randomization

First 24 hours after randomization
Hospital/30-day Mortality
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Participant vital status at hospital discharge or 30-days post randomization (whichever the earlier)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Incidence of Pre-specified Complications
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The number of participants experiencing pre-specified complications. Pre-specified complications include: Acute kidney injury; Ventilator-associated pneumonia; Multiorgan failure; Transfusion-related hyperkalemia; Transfusion-related hypocalcemia; Transfusion associated circulatory overload; Acute respiratory distress syndrome; Symptomatic and asymptomatic deep vein thrombosis; Symptomatic and asymptomatic pulmonary embolism; Bleeding after hemostasis requiring intervention; Stroke; Myocardial infarction; Abdominal compartment syndrome; Transfusion-related allergic reactions; Febrile non-hemolytic transfusion reaction; Systemic inflammatory response syndrome; Sepsis; Alloimmunization in women of childbearing age

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Adjudicated Primary Cause of Death
Periodo de tiempo: 30-days post randomization

Primary cause of death as reviewed and determined by the study investigators (consensus)

30-days post randomization
Length of Stay (Hospital and Intensive Care Unit)
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Number of hours hospitalized (includes both hospital and intensive care unit time)

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Hospital-, Ventilator- and Intensive Care Unit-free days
Periodo de tiempo: 30-days post randomization

Number of days participant was alive and out of the hospital; number of days participant was not on a ventilator; and the number of days the participant was not in the intensive care unit.

30-days post randomization
Incidence of major surgical procedures
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

The proportion of participants undergoing major surgical procedures.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Time to hemostasis in those undergoing procedures with a hemostatic component
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Time to hemostasis refers to the time that the subject achieved hemorrhage control (anatomic hemostasis and resuscitation complete) following emergency department arrival.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Number and type of blood products used until hemostasis is achieved and from hemostasis to 24 hours after randomization
Periodo de tiempo: First 24 hours after randomization

The number of units and type of blood products (e.g. whole blood, packed red blood cells, platelets, plasma, etc.)

First 24 hours after randomization
Discharge destination
Periodo de tiempo: At hospital discharge or 30-days post randomization (whichever the earlier)

Discharge destination will be measured as a categorical variable. Categories will be tallied and compared between the two study arms. Example variables include: discharged to home, discharged to another primary care facility, discharged to hospice, etc.

At hospital discharge or 30-days post randomization (whichever the earlier)
Functional status
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Functional status will be measured by Extended Glasgow Outcome Scale (GOSE). The GOSE is a tool used to measure recovery following brain injury and assists with prediction of long-term rehabilitation. The 8 scoring categories are death, vegetative state, lower severe disability, upper severe disability, lower moderate disability, upper moderate disability, lower good recovery and upper good recovery. A higher GOSE score correlates with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)
Patient's quality of life
Periodo de tiempo: From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Quality of life will be measured by the Euroqol Group's EQ-5D quality of life measurement. The EQ-5D is a patient-reported questionnaire assessing health status in terms of five dimensions of health (mobility, self-care, usual activities, pain and discomfort, and anxiety and depression). Lower EQ-5D scores are associated with better outcome.

From randomization to hospital discharge or 30-days post randomization (whichever the earlier)

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Jan Jansen, MBBS, PhD, University of Alabama at Birmingham

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

27 de julio de 2023

Finalización primaria (Actual)

4 de agosto de 2026

Finalización del estudio (Actual)

4 de agosto de 2026

Fechas de registro del estudio

Enviado por primera vez

8 de noviembre de 2022

Primero enviado que cumplió con los criterios de control de calidad

28 de noviembre de 2022

Publicado por primera vez (Actual)

6 de diciembre de 2022

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

22 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

18 de septiembre de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • IRB-300010517
  • 1UG3HL157401-01A1 (Subvención/contrato del NIH de EE. UU.)
  • 1U24HL157310-01A1 (Subvención/contrato del NIH de EE. UU.)

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

Sí

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir